- Home
- ATOS vs SNCR Comparison
ATOS vs SNCR Comparison
Compare ATOS & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- SNCR
- Stock Information
- Founded
- ATOS 2009
- SNCR 2000
- Country
- ATOS United States
- SNCR United States
- Employees
- ATOS N/A
- SNCR N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- SNCR EDP Services
- Sector
- ATOS Health Care
- SNCR Technology
- Exchange
- ATOS Nasdaq
- SNCR Nasdaq
- Market Cap
- ATOS 107.2M
- SNCR 87.5M
- IPO Year
- ATOS 2012
- SNCR 2006
- Fundamental
- Price
- ATOS $0.94
- SNCR $7.65
- Analyst Decision
- ATOS Strong Buy
- SNCR Strong Buy
- Analyst Count
- ATOS 3
- SNCR 1
- Target Price
- ATOS $6.17
- SNCR $13.00
- AVG Volume (30 Days)
- ATOS 1.5M
- SNCR 142.2K
- Earning Date
- ATOS 08-11-2025
- SNCR 08-05-2025
- Dividend Yield
- ATOS N/A
- SNCR N/A
- EPS Growth
- ATOS N/A
- SNCR N/A
- EPS
- ATOS N/A
- SNCR N/A
- Revenue
- ATOS N/A
- SNCR $172,842,000.00
- Revenue This Year
- ATOS N/A
- SNCR $2.07
- Revenue Next Year
- ATOS N/A
- SNCR $5.42
- P/E Ratio
- ATOS N/A
- SNCR N/A
- Revenue Growth
- ATOS N/A
- SNCR 4.64
- 52 Week Low
- ATOS $0.55
- SNCR $6.00
- 52 Week High
- ATOS $1.66
- SNCR $15.46
- Technical
- Relative Strength Index (RSI)
- ATOS 58.44
- SNCR 55.94
- Support Level
- ATOS $0.81
- SNCR $7.10
- Resistance Level
- ATOS $0.88
- SNCR $7.97
- Average True Range (ATR)
- ATOS 0.05
- SNCR 0.42
- MACD
- ATOS 0.01
- SNCR 0.17
- Stochastic Oscillator
- ATOS 84.07
- SNCR 75.63
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.